-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LHF-535 in Arenaviridae Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LHF-535 in Arenaviridae Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LHF-535 in Arenaviridae InfectionsDrug Details:LHF-535 is under development for the treatment of arenaviridae...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulevostinag in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Ulevostinag in Oral Cavity (Mouth) CancerDrug Details:Ulevostinag (MK-1454) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lassa Fever Vaccine in Lassa Fever (Lassa Hemorrhagic Fever)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lassa Fever Vaccine in Lassa Fever (Lassa Hemorrhagic Fever)Drug Details:Vaccine candidate is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARN-75039 in Lassa Fever (Lassa Hemorrhagic Fever)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARN-75039 in Lassa Fever (Lassa Hemorrhagic Fever) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARN-75039 in Lassa Fever (Lassa Hemorrhagic Fever)Drug Details: ARN-75039 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dalpiciclib in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dalpiciclib in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dalpiciclib in Oral Cavity (Mouth) CancerDrug Details:Dalpiciclib isethionate (Erlikon) is a...
-
Product Insights
PWD Malaysia – Muara Lassa Bridge – Sarawak
Equip yourself with the essential tools needed to make informed and profitable decisions with our PWD Malaysia - Muara Lassa Bridge - Sarawak report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Company Profile
Inovio Pharmaceuticals Inc – Company Profile
Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several...
Add to Basket -
Company Profile
GeoVax Labs Inc – Company Profile
GeoVax Labs Inc (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. It has partnerships for preclinical and clinical testing with various government, academic and corporate...
Add to Basket -
Product Insights
NewAutoimmune Technologies LLC Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Autoimmune Technologies LLC Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Autoimmune Technologies LLC (Autoimmune Technologies) operates as a biomedical company that offers research and laboratory testing services. The company offers research services in areas of MERS and SARS, influenza, hepatitis c, sjogren's syndrome, dengue fever, ebola fever and lassa fever, and graves' disease, among others. Its laboratory testing services comprise tests for fibromyalgia, ebola fever, lassa fever, gulf war...
-
Product Insights
Middle East Respiratory Syndrome (MERS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Middle East Respiratory Syndrome (MERS) Pipeline Drugs Market Report Overview Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. The MERS pipeline drugs market research report provides comprehensive information on the MERS targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players...